Literature DB >> 31948751

The regulation of HAS3 by miR-10b and miR-29a in neuroendocrine transdifferentiated LNCaP prostate cancer cells.

Elena D Czyrnik1, Marc Wiesehöfer1, Jaroslaw T Dankert2, Gunther Wennemuth3.   

Abstract

Prostate cancer (PCa) is the second most common type of cancer in male worldwide. During neuroendocrine transdifferentiation (NETD), PCa cells are able to differentiate into androgen-independent neuroendocrine-like (NE-like) tumor cells, which are associated with reduced survival rates in PCa patients. The molecular processes underlying NETD have not been clarified yet, but miRNAs could play a potential role. MiRNAs are short, single-stranded, non-coding RNA molecules that regulate gene expression post-transcriptionally by binding to the 3'-untranslated region (3'UTR) of their target mRNAs. This study aimed to explore the possible relevance and function of the transmembrane Hyaluronan Synthase 3 (HAS3) and miR-10b as well as miR-29a during NETD. Here, we validated a repression of HAS3 and an induction of miR-10b and miR-29a by quantitative real-time PCR after NETD. HAS3 was predicted as a new target gene for both miRNAs, which was verified by Reporter Gene Assays and Western Blotting. Functional analyses revealed an inhibiting effect of HAS3 on cell proliferation and migration in LNCaP cells, whereas miR-10b showed no impact. Furthermore, HAS3 increased the colony forming ability, while miR-10b diminished it. These results might give a hint on the role of miR-10b and HAS3 during NETD of PCa cells.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HAS3; LNCaP; Neuroendocrine transdifferentiation; Prostate cancer; miR-10b; miR-29a

Mesh:

Substances:

Year:  2020        PMID: 31948751     DOI: 10.1016/j.bbrc.2020.01.026

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  A novel 8-gene panel for prediction of early biochemical recurrence in patients with prostate cancer after radical prostatectomy.

Authors:  Jinan Guo; Chenhui Zhao; Xinzhou Zhang; Zhong Wan; Tingting Chen; Jiashun Miao; Jinping Cai; Wenchuan Xie; Hao Chen; Mengli Huang; Xiaochen Zhao; Wei Wei; Qi Shen
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

2.  Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome.

Authors:  Siri H Strand; Linnéa Schmidt; Simone Weiss; Michael Borre; Helle Kristensen; Anne Karin Ildor Rasmussen; Tina Fuglsang Daugaard; Gitte Kristensen; Hein Vincent Stroomberg; Martin Andreas Røder; Klaus Brasso; Peter Mouritzen; Karina Dalsgaard Sørensen
Journal:  Sci Rep       Date:  2020-07-01       Impact factor: 4.379

Review 3.  Role of MicroRNAs in Neuroendocrine Prostate Cancer.

Authors:  Amritha Sreekumar; Sharanjot Saini
Journal:  Noncoding RNA       Date:  2022-03-30

4.  The Oral Tumor Cell Exosome miR-10b Stimulates Cell Invasion and Relocation via AKT Signaling.

Authors:  Xiang Li; Ting Yang; Chuanji Shu
Journal:  Contrast Media Mol Imaging       Date:  2022-08-16       Impact factor: 3.009

5.  Loss of RBMS1 as a regulatory target of miR-106b influences cell growth, gap closing and colony forming in prostate carcinoma.

Authors:  Jaroslaw Thomas Dankert; Marc Wiesehöfer; Sven Wach; Elena Dilâra Czyrnik; Gunther Wennemuth
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.